Future Immunotherapies in Multiple Sclerosis Future Immunotherapies in Multiple Sclerosis2018-01-17T17:01:53-05:00
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon B Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon B2018-01-17T17:00:33-05:00